| Ytd | -88.09% | |
| 1y | -82.72% |
| Open | 4.93 | Prev Close | 4.90 | Low | 4.83 | High | 5.12 | Mkt Cap | 221.54M |
| Vol | 633.56K | Avg Vol | 2.19M | EPS | -2.16 | P/E | N/A | Forward P/E | -18.18 |
| Beta | 1.00 | Short Ratio | 10.62 | Inst. Own | 100.23% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-05 | 50-d Avg | 12.02 | 200-d Avg | 33.03 | 1yr Est | 53.20 |
SION News
Previously disclosed post hoc PreciSION CF analyses of SION-719 support advancement of SION-451 + SI
Sionna Therapeutics, Inc. (NASDAQ: SION - Get Free Report) has been given an average recommendation
NEW YORK, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of inves
NEW YORK, Oct. 1, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors
NEW YORK, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of inve
NEW YORK, Sept. 24, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investor
NEW YORK, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of inve
Tax-loss selling is likely to lead these 20 stocks to become artificially depressed in the fourth qu
NEW YORK, Sept. 17, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investor
Sionna set to reduce its workforce by 46% after SION-719 fails a key CF study, shifting focus to SIO
Sionna Therapeutics, Inc. (NASDAQ: SION - Get Free Report) has earned a consensus rating of "Hold" f
NEW YORK, Sept. 15, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of inve
Wedbush analyst Laura Chico maintains Sionna Therapeutics (NASDAQ:SION) with a Neutral and raises
Sionna Therapeutics, Inc. (SION) Discusses Post-Hoc Analysis of PreciSION CF Trial and Advancement o
Post hoc analyses of SION-719 PreciSION CF subset showed a mean placebo-adjusted sweat chloride redu
Post hoc analyses of SION-719 PreciSION CF subset showed a mean placebo-adjusted sweat chloride redu
NEW YORK, Sept. 10, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investor
NEW YORK, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of inve
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sionna Therapeutics
NEW YORK, Sept. 3, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered L
NEW YORK, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of inve
Gainers BioVie (NASDAQ:BIVI) shares increased by 39.4% to $1.77 during Wednesday's regular sess
Wedbush analyst Laura Chico downgrades Sionna Therapeutics (NASDAQ:SION) from Outperform to Neutr
Sionna Therapeutics topline clinical data for cystic fibrosis programs disappoints, opting to discon
Gainers Jin Medical International (NASDAQ:ZJYL) shares rose 58.1% to $3.4 during Monday's regul
US stocks mixed, Dow Jones down 0.2% midday. Energy shares up 3%, real estate down 1.4%. National En
Dow Jones fell 0.2% as US stocks opened lower. Energy shares rose 1.9%, while real estate stocks dro
Gainers Jin Medical International (NASDAQ:ZJYL) stock rose 70.7% to $3.67 during Monday's pre-m
Sionna Therapeutics, Inc. (NASDAQ:SION), a clinical-stage biopharmaceutical company on a mission to
Guggenheim analyst Yatin Suneja maintains Sionna Therapeutics (NASDAQ:SION) with a Buy and raises
Sionna Therapeutics (NASDAQ:SION) reported quarterly losses of $(0.66) per share which missed the an
Citizens analyst Jonathan Wolleben reiterates Sionna Therapeutics (NASDAQ:SION) with a Market Out
Stifel analyst Paul Matteis maintains Sionna Therapeutics (NASDAQ:SION) with a Buy and raises the
BTIG analyst Kambiz Yazdi reiterates Sionna Therapeutics (NASDAQ:SION) with a Buy and maintains $
Sionna Therapeutics (NASDAQ:SION) reported quarterly losses of $(0.60) per share which missed the an
Top Wall Street analysts changed outlook on top names. Check analyst ratings page for full changes.
Top Wall Street analysts changed outlook on top names. See analyst ratings page for all changes. Cit
Wedbush analyst Laura Chico initiates coverage on Sionna Therapeutics (NASDAQ:SION) with a Outper
Jones Trading analyst Debanjana Chatterjee maintains Sionna Therapeutics (NASDAQ:SION) with a Buy
BTIG analyst Kambiz Yazdi reiterates Sionna Therapeutics (NASDAQ:SION) with a Buy and maintains $
Sionna Therapeutics, Inc. (NASDAQ:SION), a clinical-stage biopharmaceutical company on a mission to
Guggenheim analyst Yatin Suneja maintains Sionna Therapeutics (NASDAQ:SION) with a Buy and raises
BTIG analyst Kambiz Yazdi reiterates Sionna Therapeutics (NASDAQ:SION) with a Buy and maintains $
Citizens analyst Jonathan Wolleben initiates coverage on Sionna Therapeutics (NASDAQ:SION) with a
BTIG analyst Kambiz Yazdi reiterates Sionna Therapeutics (NASDAQ:SION) with a Buy and maintains $
BTIG analyst Kambiz Yazdi maintains Sionna Therapeutics (NASDAQ:SION) with a Buy and raises the p
LifeSci Capital analyst Cory Jubinville initiates coverage on Sionna Therapeutics (NASDAQ:SION) w